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Abstract
Decreased in vitro susceptibility to dihydroartemisinin (21.2 nM) and artesunate (16.3 nM) associated with
decreased susceptibility or resistance to quinine (1131 nM), mefloquine (166 nM), lumefantrine (114 nM),
pyronaridine (70.5 nM) and piperaquine (91.1 nM) is reported in a patient returning from South-East Asia after
trekking along the Mekong from the south of Laos to the north of Thailand. Decreased in vitro susceptibility to
artemisinin derivatives did not appear to be mediated by the number of copies of pfmdr1 or pfATPase6, pfcrt,
pfmdr1 or pfmrp polymorphism. The high IC50 to mefloquine of this Asian isolate was not associated with pfmdr1
copy number. Pfnhe-1 microsatellite ms4760 showed a profile 7 (ms4760-7) with three repeats of DNNND and one
repeat of DDDNHNDNHNN, which is associated with high quinine reduced susceptibility. The patient recovered in
three days without relapse after treatment with the association of quinine and doxycycline. Decreased in vitro
susceptibility to quinine and the delayed effect of doxycycline may both have contributed to the delayed parasite
clearance time, D4 (0.5%) and D7 (0.004%). The in vitro data, with IC50 for dihydroartemisinin and artesunate were
up to ten times those of the reference clone W2, which suggests that this isolate may be resistant to artemisinin
derivatives, associated with a decreased susceptibility to quinine.
Background
Artemisinin-based combination therapy (ACT) is now
recommended by the World Health Organization as first-
line treatment of uncomplicated falciparum malaria in all
areas in which malaria is endemic. However, recent
reports from Cambodia of delayed parasite clearance after
treatment by ACT have now been confirmed [1]. The
resistant phenotype is not yet reflected by the results of
conventional in vitro drug susceptibility assays. Parasites
with slow clearance rate after ACT did not show in vitro
decreased susceptibility [1]. In vitro decreased susceptibil-
ity to artemisinin derivatives was never or very rarely
reported in Cambodia [1-4]. No molecular marker has
been identified, which impedes surveillance studies to
monitor the spread of artemisinin resistant phenotype.
Decrease of in vitro susceptibility to dihydroartemisinin
and artesunate, associated with reduced susceptibility to
standard anti-malarials, such as quinine, mefloquine and
lumefantrine, and new drugs, such as pyronaridine and
piperaquine, is reported here.
Case presentation
A 52-year old female visited rural areas in Laos (Nov 9 to
12, 2009), Cambodia (Nov 12 to 29) and Thailand (Nov
29 to Dec 1). She took part in trekking along the Mekong
from the south of Laos to the north of Thailand.
The patient presented with fever since November 29 and
was hospitalized (Dec 2) in int e n s i v ec a r eu n i t( C e n t r e
Hospitalier Universitaire l’Archet, Nice, France) for com-
plicated malaria (15% parasitaemia and altered con-
sciousness). The patient used irregularly doxycycline (100
mg/day) as chemoprophylaxis. The patient was treated
by intra-venous quinine chlorhydrate (25 mg/kg/day) and
doxycycline (200 mg/day) for seven days. The patient
recovered in three days without relapse and was
discharged.
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Day 0 (15%), D4 (0.5%) and D7 (0.004%) but were not
detected at D43.
Methods
In vitro testing of drug susceptibility was performed by the
standard 42-hour
3H-hypoxanthine uptake inhibition
method [5]. Susceptibility to dihydroartemisinin, artesu-
nate, and ten standard or new anti-malarial drugs, ie
chloroquine, quinine, mefloquine, lumefantrine, monode-
sethylamodiaquine (biologically active metabolite of amo-
diaquine), pyronaridine, piperaquine, atovaquone,
doxycycline and pyrimethamine, was assessed. The labora-
tory-adapted clone W2, tested on the same day, was used
as a reference. Isolates from imported malaria, tested on
the same batch of plates, were used as comparators.
Polymorphisms of pfcrt, pfmdr1, pfmrp and pfnhe-1,
involved in quinoline resistance, and in pfATPase6, postu-
lated to be involved in artemisinin resistance, and the copy
number of pfmdr1 were assessed [6].
The French malaria consensus [7] and the WHO [8]
recommend to clinically examine patient and control para-
sitaemia at D0, D3, D7 and D28 to evaluate anti-malarial
efficacy. Blood controls were performed at D0, D4, D7 and
D43. The genotyping of parasites was assessed at D0, D4
and D7 using six microsatellite loci (microsatellites 7A11,
pf2689, pf2802, C4M79, TRAP, C4M69) [9], msp1 and
msp2 [10].
Consent
Informed consent was not required as the sampling proce-
dures and testing are part of the French national recom-
mendations for the care and surveillance of malaria.
Results
This isolate showed decreased susceptibility to dihydroar-
temisinin (21.2 nM) and artesunate (16.3 nM) associated
with decreased susceptibility or resistance to quinine
(1131 nM), mefloquine (166 nM), lumefantrine (114 nM),
pyronaridine (70.5 nM) and piperaquine (91.1 nM) with
high ratio in comparison with W2 (Table 1). These IC50
and W2 ratios were higher than those of other imported
isolates.
Mutations were not identified in pfmdr1, pfcrt and
pfmrp genes. Only one copy of pfmdr1 was found. Two
synonymous mutations were detected in pfATPase6
(N460N and I898I), which were previously described
[11]. Pfnhe-1 microsatellite ms4760 showed a profile 7
(ms4760-7) with three repeats of DNNND and one
repeat of DDDNHNDNHNN, which is associated with
high quinine reduced susceptibility [12].
Parasitaemia was controlled at Day 0, D4, D7 and D43.
Monoclonal and identical parasites were identified at D0
(15% of parasitaemia), D4 (0.5%) and D7 (0.004%) by
using microsatellites 7A11, pf2689, pf2802, C4M79,
TRAP, C4M69 and msp1 and msp2. No parasite was
detected at D43.
Conclusion
This isolate showed reduced susceptibility to artemisinin
derivatives, but also to other ACT components commonly
used in Asia or in clinical trials, such as mefloquine, lume-
fantrine, pyronaridine or piperaquine. Surprising, this iso-
late was susceptible in vitro to chloroquine and
monodesethylamodiaquine. It was also susceptible to dox-
ycycline. Plasmodium falciparum parasite with high IC50
to artemisinin and artemether (20.1 nM and 21.4 nM,
respectively), but with low IC50 to dihydroartemisinin and
artesunate (1.8 nM and 6.2 nM, respectively) was recently
isolated in a traveller returning from Nigeria, who took
artesunate prophylactically (two 50 mg tablets weekly for
4 weeks) [13]. Yet, recent clinical trials of oral artesunate
monotherapy suggest that the loss of ACT efficacy might
result from decreased efficacy of artemisinin derivatives
[1,3]. The median parasite clearance time was 36 hours
longer in patients from Western Cambodia, where the effi-
cacy of ACT is decreasing [1]. Nevertheless, this phenom-
enon was not correlated with artemisinin derivatives IC50.
Only one copy of pfmdr1 was found. The high IC50 to
mefloquine of this Asian isolate was not associated with
pfmdr1 copy number. Pfnhe-1 microsatellite ms4760
showed a profile 7 (ms4760-7) with three repeats of
DNNND and one repeat of DDDNHNDNHNN, which is
associated with high quinine reduced susceptibility [12].
T w or e p e a t so fD N N N Dw e r es e e nt ob ea s s o c i a t e dw i t h
high IC50 in quinine clinical failure in traveller from
Senegal [14].
The persistence of parasites seven days after the start of
treatment with quinine chlorhydrate and doxycycline, but
without clinical signs, is consistent with the high IC50 and
with the profile ms4760 of pfnhe-1. The action of doxycy-
cline is delayed. There is a relationship between the
amount and duration of exposure and the effect of doxy-
cycline on the erythrocytic stages with an increased activ-
ity during the second cycle. Doxycycline has been shown
to exert its effect during the first 48 h, but is only detect-
able in second-generation parasites near the 96 hour time
point [15-17]. The French malaria consensus recommends
quinine associated with doxycycline for Asian and South-
American P. falciparum (and not only quinine as for Afri-
can parasites). Clinical failure with quinine has been
shown in a patient returning from French Guiana treated
by quinine only [18]. The patient recovered in three days
without relapse and left intensive care due to the treat-
ment she received, the association of quinine and doxycy-
cline, as recommended by the French malaria consensus.
In vitro quinine IC50 and pfnhe-1 ms4760 analysis suggest
a reduced susceptibility to quinine. This decreased
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cline may both have contributed to the delayed parasite
clearance time, D4 (0.5%) and D7 (0.004%).
Decreased in vitro susceptibility to artemisinin deriva-
tives did not appear to be mediated by the number of
copies of pfmdr1 or pfATPase6 polymorphism. The in
vitro data, with IC50 for dihydroartemisinin and artesunate
up to ten times those of the reference clone W2 or the
geometric mean of the other isolates, suggest that this iso-
late could be resistant to artemisinin derivatives, even if
there is no evidence that this isolate was clinically resistant
to ACT, associated with decreased susceptibility to qui-
nine. And its association with the other in vitro decreased
susceptibilities is alarming, especially with the components
of ACT used in Asia.
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